Why it may matterVerify against the original reporting
Despite an EPS beat, sales decline and poor Hawthorne performance indicate challenges. Historically, sales misses have negatively impacted stock prices.
AI summary
What happened, with direct paths to the underlying reporting
SMG's Q2 2025 EPS rose 8% to $3.98, above consensus. Sales fell 7% year-over-year to $1.42 billion, missing expectations. U.S. consumer sales decreased 5%, affected by a slow lawn season. Hawthorne sales plummeted 51% to $32.7 million amidst cannabis uncertainties. Adjusted EBITDA was $402.8 million, showing slight improvement year-over-year.
SMG's Q2 2025 EPS rose 8% to $3.98, above consensus.
Sales fell 7% year-over-year to $1.42 billion, missing expectations.
U.S. consumer sales decreased 5%, affected by a slow lawn season.
Hawthorne sales plummeted 51% to $32.7 million amidst cannabis uncertainties.
Adjusted EBITDA was $402.8 million, showing slight improvement year-over-year.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Jim Cramer has recommended avoiding tobacco stocks, particularly Altria Group (NYSE:MO), while highlighting the increasing demand for LNG as a potential growth driver for companie…
Scotts Miracle-Gro plans to separate Hawthorne to boost its valuation. Hawthorne's sales fell 35% to $52 million in the first fiscal quarter. Analyst sees separation as a positive…
- Scotts Miracle-Gro reported $1.53 billion revenue, down 0.4% from last year. - EPS was $3.69 compared to $3.78 in the previous year. - Net sales varied for different segments, i…